Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23627568)

1.

Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis.

Kong M, Zhang J, Jiang C, Jiang X, Li Y, Gao M, Yao N, Huang D, Wang X, Fang Z, Liu W, Sun Z, Ni Y.

J Drug Target. 2013 Jul;21(6):604-10. doi: 10.3109/1061186X.2013.789034. Epub 2013 Apr 29.

PMID:
23627568
2.

Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.

Cona MM, Alpizar YA, Li J, Bauwens M, Feng Y, Sun Z, Zhang J, Chen F, Talavera K, de Witte P, Verbruggen A, Oyen R, Ni Y.

Pharm Res. 2014 Feb;31(2):278-90. doi: 10.1007/s11095-013-1159-4. Epub 2013 Aug 9.

PMID:
23934256
3.

Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.

Cona MM, Koole M, Feng Y, Liu Y, Verbruggen A, Oyen R, Ni Y.

Int J Oncol. 2014 Mar;44(3):819-29. doi: 10.3892/ijo.2013.2217. Epub 2013 Dec 17.

PMID:
24366374
4.

Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations.

Cona MM, Li J, Feng Y, Chen F, Verbruggen A, Witte Pd, Oyen R, Ni Y.

Anticancer Agents Med Chem. 2014;14(6):852-61.

PMID:
24102315
5.

Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis.

Ji Y, Zhan Y, Jiang C, Jiang X, Gao M, Liu W, Li Y, Wang J, Wang Q, Cona MM, Yao N, Wang X, Fang Z, Yin Z, Zhang J, Sun Z, Ni Y.

J Drug Target. 2014 May;22(4):304-12. doi: 10.3109/1061186X.2013.867962. Epub 2013 Dec 13.

PMID:
24328682
6.

Radiopharmaceutical evaluation of 131I-protohypericin as a necrosis avid compound.

Liu X, Feng Y, Jiang C, Lou B, Li Y, Liu W, Yao N, Gao M, Ji Y, Wang Q, Huang D, Yin Z, Sun Z, Ni Y, Zhang J.

J Drug Target. 2015 Feb 6:1-10. [Epub ahead of print]

PMID:
25655506
7.

Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats.

Cona MM, Feng Y, Verbruggen A, Oyen R, Ni Y.

Exp Biol Med (Maywood). 2013 Dec;238(12):1437-49. doi: 10.1177/1535370213508235. Epub 2013 Oct 21.

PMID:
24146264
8.

Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.

Lahorte CM, Bacher K, Burvenich I, Coene ED, Cuvelier C, De Potter C, Thierens H, Van de Wiele C, Dierckx RA, Slegers G.

J Nucl Med. 2004 Jun;45(6):1065-73.

9.

Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis.

Qi X, Shao H, Zhang J, Sun Z, Ni Y, Xu K.

Radiol Med. 2015 Feb;120(2):213-21. doi: 10.1007/s11547-014-0433-9. Epub 2014 Jul 11.

PMID:
25012473
10.

First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent.

Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM, Bormans GM.

Eur J Nucl Med Mol Imaging. 2006 May;33(5):595-601. Epub 2006 Feb 1.

PMID:
16450141
11.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

12.

Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model.

Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW, Ting G.

Nucl Med Biol. 2007 May;34(4):415-23.

PMID:
17499731
13.

Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models.

Li J, Cona MM, Chen F, Feng Y, Zhou L, Yu J, Nuyts J, de Witte P, Zhang J, Himmelreich U, Verbruggen A, Ni Y.

Theranostics. 2012;2(10):1010-9. doi: 10.7150/thno.4924. Epub 2012 Oct 18.

14.

Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction.

Cona MM, Feng Y, Zhang J, Li Y, Verbruggen A, Oyen R, Ni Y.

Drug Deliv. 2014 Jan 13. [Epub ahead of print]

PMID:
24417698
15.

Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.

Marysael T, Ni Y, Lerut E, de Witte P.

J Cancer Res Clin Oncol. 2011 Nov;137(11):1619-27. doi: 10.1007/s00432-011-1032-y. Epub 2011 Aug 21.

PMID:
21858709
16.

Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats.

Chang CH, Chou TK, Yang CY, Chang TJ, Wu YH, Lee TW.

In Vivo. 2008 Nov-Dec;22(6):693-7.

17.

Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.

Marysael T, Bauwens M, Ni Y, Bormans G, Rozenski J, de Witte P.

Invest New Drugs. 2012 Dec;30(6):2132-40. doi: 10.1007/s10637-011-9778-2. Epub 2011 Dec 21.

PMID:
22187204
18.

Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent.

Zhang D, Huang D, Ji Y, Jiang C, Li Y, Gao M, Yao N, Liu X, Shao H, Jing S, Ni Y, Yin Z, Zhang J.

J Drug Target. 2015 Feb;23(2):180-90. doi: 10.3109/1061186X.2014.971328. Epub 2014 Oct 20.

PMID:
25330022
19.

Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate.

Patt M, Solbach C, Wüllner U, Blocher A, Stahlschmidt A, Gündisch D, Kovar KA, Machulla HJ.

J Pharm Pharm Sci. 2007;10(2):312s-320s.

20.

Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Lin WY, Lin CP, Yeh SJ, Hsieh BT, Tsai ZT, Ting G, Yen TC, Wang SJ, Knapp FF Jr, Stabin MG.

Eur J Nucl Med. 1997 Jun;24(6):590-5.

PMID:
9169563
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk